These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 2067036)

  • 1. Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response.
    Aebersold P; Hyatt C; Johnson S; Hines K; Korcak L; Sanders M; Lotze M; Topalian S; Yang J; Rosenberg SA
    J Natl Cancer Inst; 1991 Jul; 83(13):932-7. PubMed ID: 2067036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth and autologous tumor lysis by tumor-infiltrating lymphocytes from metastatic melanoma expanded in interleukin-2 or interleukin-2 plus interleukin-4.
    Lindgren CG; Thompson JA; Higuchi CM; Fefer A
    J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):322-8. PubMed ID: 8280715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2.
    Arienti F; Belli F; Rivoltini L; Gambacorti-Passerini C; Furlan L; Mascheroni L; Prada A; Rizzi M; Marchesi E; Vaglini M
    Cancer Immunol Immunother; 1993 May; 36(5):315-22. PubMed ID: 8477417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of HC antibody in autologous tumor-specific cytotoxicity by human melanoma tumor-infiltrating lymphocytes.
    Mansfield PF; Salmeron MA; Rosenblum MG; Itoh K
    Int J Cancer; 1991 Sep; 49(3):356-61. PubMed ID: 1917133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.
    Rosenberg SA; Yannelli JR; Yang JC; Topalian SL; Schwartzentruber DJ; Weber JS; Parkinson DR; Seipp CA; Einhorn JH; White DE
    J Natl Cancer Inst; 1994 Aug; 86(15):1159-66. PubMed ID: 8028037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of lymphokine-activated killer cell generation by tumor-infiltrating lymphocytes.
    Chakraborty NG; Sporn JR; Pasquale DR; Ergin MT; Mukherji B
    Clin Immunol Immunopathol; 1991 Jun; 59(3):407-16. PubMed ID: 2029793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction.
    Hom SS; Topalian SL; Simonis T; Mancini M; Rosenberg SA
    J Immunother (1991); 1991 Jun; 10(3):153-64. PubMed ID: 1868040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.
    Wu R; Forget MA; Chacon J; Bernatchez C; Haymaker C; Chen JQ; Hwu P; Radvanyi LG
    Cancer J; 2012; 18(2):160-75. PubMed ID: 22453018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism.
    Gamero AM; Ussery D; Reintgen DS; Puleo CA; Djeu JY
    Cancer Res; 1995 Nov; 55(21):4988-94. PubMed ID: 7585540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expansion of tumor-infiltrating lymphocytes from human tumors using the T-cell growth factors interleukin-2 and interleukin-4.
    Kawakami Y; Haas GP; Lotze MT
    J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):336-47. PubMed ID: 8280717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced interleukin-2 production in human tumor-infiltrating lymphocytes engineered by 3'-truncated interleukin-2 gene.
    Yamaue H; Kashmiri SV; De Filippi R; Nieroda C; Yannelli JR; Tsang KY; Schlom J
    J Immunother Emphasis Tumor Immunol; 1994 Nov; 16(4):262-74. PubMed ID: 7881635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
    Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
    J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
    Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
    J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-infiltrating lymphocyte therapy for melanoma: rationale and issues for further clinical development.
    Sim GC; Chacon J; Haymaker C; Ritthipichai K; Singh M; Hwu P; Radvanyi L
    BioDrugs; 2014 Oct; 28(5):421-37. PubMed ID: 24890028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies.
    Itoh K; Balch CM; Murray JL; Parkinson DR; Markowitz AB; Talpaz M; Lee K; Zukiwski AA; Ross MI; Legha SS
    In Vivo; 1991; 5(6):647-53. PubMed ID: 1810451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human melanoma-mediated inhibition of autologous CD4+ helper tumor-infiltrating lymphocyte growth in vitro.
    Darrow TL; Wahab Z; Quinn-Allen MA; Seigler HF
    Cancer; 1992 Apr; 69(7):1843-9. PubMed ID: 1532342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes. Possible mechanisms for immunotherapeutic failures.
    Topalian SL; Kasid A; Rosenberg SA
    J Immunol; 1990 Jun; 144(11):4487-95. PubMed ID: 2160503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphokine-activated killer (LAK) cell activity in tumor-infiltrating lymphocytes from non-small cell lung cancer.
    Pisani RJ; Krco CJ; Wold LE; McKean DJ
    Am J Clin Pathol; 1989 Oct; 92(4):435-46. PubMed ID: 2552792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The antitumor effects of tumor-infiltrating lymphocytes (TIL) being proliferated in vitro].
    Zhang BX
    Zhonghua Bing Li Xue Za Zhi; 1992 Apr; 21(2):79-81. PubMed ID: 1499075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients.
    Saint-Jean M; Knol AC; Volteau C; Quéreux G; Peuvrel L; Brocard A; Pandolfino MC; Saiagh S; Nguyen JM; Bedane C; Basset-Seguin N; Khammari A; Dréno B
    J Immunol Res; 2018; 2018():3530148. PubMed ID: 29750176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.